drugset / Trial / NCT03447470
Study to Evaluate the Safety and Tolerability of RXC004 in Advanced Malignancies
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to determine the safety and tolerability of RXC004 as monotherapy and in combination with Nivolumab in patients with advanced malignancies. In order to define the doses and schedules for further clinical evaluation.
Timeline
- Start
- 2019-03-18
- Primary completion
- 2023-09-29
- Completion
- 2023-09-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nivolumab | Monoclonal antibody | — | — |
| Subject | ZAMAPORVINT | Small molecule | 0.5 mg | Oral |
| Subject | ZAMAPORVINT | Small molecule | 1 mg | Oral |
| Subject | ZAMAPORVINT | Small molecule | 1.5 mg | Oral |
| Subject | ZAMAPORVINT | Small molecule | 2 mg | Oral |
| Subject | ZAMAPORVINT | Small molecule | 3 mg | Oral |
| Subject | ZAMAPORVINT | Small molecule | 10 mg | Oral |